 |
W2O handles media for MyoKardia as the clinical biopharmaceutical firm agrees to be acquired by Bristol-Myers-Squibb for $13.1B in cash, which represents a 60 percent premium over the California-based company’s Oct. 2 closing stock price.
BMS CEO Giovanni Caforio said MyKardia’s mavacamten cardiovascular drug was a key reason for the deal.
He called mavacamten, “a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease.”
Mavacamten treats obstructive hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes too thick.
There are 160K to 200K people in the US and EU diagnosed with HCM, which has no effective treatment. It’s estimated that only 25 percent of people with HCM receive a diagnosis.
MyoKardia expects to file a new drug application for mavacamten with the Food & Drug Administration during the first quarter of 2021.
W2O’s Julie Nomert handles MyoKardia, while Hannah Deresiewicz of Stern Investor Relations handles Wall Street.
Kekst CNC represents RenaissanceRe Holdings as it acquires American International Group’s Validus Reinsurance in a deal valued at $3B.
FTI Consulting's Tristan Peniston-Bird has joined Portland’s London office as senior partner and financial communications lead in its corporate communications practice.
Joele Frank is handling Chevron’s acquisition of Denver-based PDC Energy via an all-stock transaction valued at $6.3B.
Joele Frank is handling the Chapter 11 filing of Vice Media Group as it arranges a $225M bailout from Soros Fund Management, Fortress Investment Group and Monroe Capital.
Kekst CNC is handling the Chapter 11 filing of Buffalo-based Athenex Inc., a biopharmaceutical company focused on cancer treatments.
Have a comment? Send it to 
No comments have been submitted for this story yet.